Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(2):306–309. doi: 10.1038/bjc.1997.50

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.

M Fukuoka 1, N Masuda 1, S Negoro 1, K Matsui 1, T Yana 1, S Kudoh 1, Y Kusunoki 1, M Takada 1, M Kawahara 1, M Ogawara 1, N Kodama 1, K Kubota 1, K Furuse 1
PMCID: PMC2063260  PMID: 9010043

Abstract

Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs (P = 0.03) with a significant improvement in survival (P = 0.004).

Full text

PDF
307

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisner J., Alberto P., Bitran J., Comis R., Daniels J., Hansen H., Ikegami H., Smyth J. Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep. 1983 Jan;67(1):37–43. [PubMed] [Google Scholar]
  2. Alba E., Breton J. J., Alonso L., Paredes G., Belon J., Ballesteros P. Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs. Ann Oncol. 1992 Jan;3(1):31–35. doi: 10.1093/oxfordjournals.annonc.a058062. [DOI] [PubMed] [Google Scholar]
  3. Bronchud M. H., Scarffe J. H., Thatcher N., Crowther D., Souza L. M., Alton N. K., Testa N. G., Dexter T. M. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987 Dec;56(6):809–813. doi: 10.1038/bjc.1987.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., Kris M., Grous J., Picozzi V., Rausch G. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991 Jul 18;325(3):164–170. doi: 10.1056/NEJM199107183250305. [DOI] [PubMed] [Google Scholar]
  5. Frei E., 3rd, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585–594. doi: 10.1016/0002-9343(80)90472-6. [DOI] [PubMed] [Google Scholar]
  6. Fukuoka M., Masuda N., Takada M., Kodama N., Kawahara M., Furuse K. Dose-intensive chemotherapy in extensive-stage small cell lung cancer. Semin Oncol. 1994 Feb;21(1 Suppl 1):43–47. [PubMed] [Google Scholar]
  7. Masuda N., Fukuoka M., Furuse K. CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer. Oncology. 1992;49 (Suppl 1):19–24. doi: 10.1159/000227106. [DOI] [PubMed] [Google Scholar]
  8. Miles D. W., Earl H. M., Souhami R. L., Harper P. G., Rudd R., Ash C. M., James L., Trask C. W., Tobias J. S., Spiro S. G. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol. 1991 Feb;9(2):280–285. doi: 10.1200/JCO.1991.9.2.280. [DOI] [PubMed] [Google Scholar]
  9. Miles D. W., Fogarty O., Ash C. M., Rudd R. M., Trask C. W., Spiro S. G., Gregory W. M., Ledermann J. A., Souhami R. L., Harper P. G. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol. 1994 Jan;12(1):77–82. doi: 10.1200/JCO.1994.12.1.77. [DOI] [PubMed] [Google Scholar]
  10. Murray N., Osoba D., Shah A., Page R., Karsai H., Little C. Brief intensive chemotherapy for metastatic non-small-cell lung cancer: a phase II study of the weekly CODE regimen. J Natl Cancer Inst. 1991 Feb 6;83(3):190–194. doi: 10.1093/jnci/83.3.190. [DOI] [PubMed] [Google Scholar]
  11. Murray N., Shah A., Osoba D., Page R., Karsai H., Grafton C., Goddard K., Fairey R., Voss N. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol. 1991 Sep;9(9):1632–1638. doi: 10.1200/JCO.1991.9.9.1632. [DOI] [PubMed] [Google Scholar]
  12. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Taylor C. W., Crowley J., Williamson S. K., Miller T. P., Taylor S. A., Giri T. G., Stephens R. L., Livingston R. B. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. J Clin Oncol. 1990 Nov;8(11):1811–1817. doi: 10.1200/JCO.1990.8.11.1811. [DOI] [PubMed] [Google Scholar]
  14. Trillet-Lenoir V., Green J., Manegold C., Von Pawel J., Gatzemeier U., Lebeau B., Depierre A., Johnson P., Decoster G., Tomita D. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A(3):319–324. doi: 10.1016/0959-8049(93)90376-q. [DOI] [PubMed] [Google Scholar]
  15. Wampler G. L., Ahlgren J. D., Schulof R. S. A pilot study of intensive weekly chemotherapy for extensive disease small-cell lung carcinoma. Cancer Invest. 1992;10(2):97–102. doi: 10.3109/07357909209032770. [DOI] [PubMed] [Google Scholar]
  16. Woll P. J., Hodgetts J., Lomax L., Bildet F., Cour-Chabernaud V., Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol. 1995 Mar;13(3):652–659. doi: 10.1200/JCO.1995.13.3.652. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES